Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Wockhardt Limited ( (IN:WOCKPHARMA) ).
Wockhardt Limited, the pharmaceutical and biotechnology major, has reported a strong turnaround in profitability for the quarter and financial year ended 31 March 2026, driven by robust revenue and EBITDA growth. The company posted profit before tax of Rs. 189 crore for Q4 FY26 versus a loss of Rs. 22 crore a year earlier, and a full-year profit before tax of Rs. 238 crore compared with a loss of Rs. 16 crore, underscoring improved operational efficiency and financial health.
For the fourth quarter, Wockhardt’s revenue rose 30% year-on-year to Rs. 965 crore, while EBITDA surged 147% to Rs. 196 crore, signaling strong operating leverage. Over the full FY26, revenue increased 11% to Rs. 3,373 crore and EBITDA climbed 51% to Rs. 630 crore, reinforcing the company’s recovery trajectory and potentially strengthening its competitive position and confidence among investors and other stakeholders.
More about Wockhardt Limited
Wockhardt Limited is a pharmaceutical and biotechnology company with a focus on developing and manufacturing medicines for global markets. Listed in India, it operates through both standalone and consolidated entities, reflecting a diversified portfolio across formulations and allied healthcare segments.
Average Trading Volume: 41,460
Technical Sentiment Signal: Strong Buy
Current Market Cap: 226.6B INR
For detailed information about WOCKPHARMA stock, go to TipRanks’ Stock Analysis page.